LUPIN.NSE Lupin Ltd
275
1,646.00
38.00
(2.26%)
| Watchers | 275 |
| 52-Wk Low | 769.60 |
| 52-Wk High | 1,704.25 |
| Market Cap | 769.58B |
| Volume | 550,560.00 |
| 52-Wk High | 1,704.25 |
| 52-Wk Low | 769.60 |
Chartist Talks: Milan Vaishnav believes these 2 largecaps are in a structural uptrend, should be in portfolioMoneycontrol • about 4 hours ago
Vaishnav said he would prefer stocks with improving relative strength and low beta and believes Lupin and Tata Consultancy Services fit the bill.
Share to Feed
Kindler is currently the CEO of Centrexion Therapeutics, a privately-held biotechnology company, Senior Advisor to Blackstone, Operating Partner at ARTIS Ventures and Global Chair of GLG Institute, Lupin said in a regulatory filing.
Motilal Oswal recommended accumulate rating on Lupin with a target price of Rs 1,550 in its research report dated May 08, 2024.
Sharekhan is bullish on Lupin has recommended buy rating on the stock with a target price of Rs 1868 in its research report dated May 07, 2024.
Prabhudas Lilladher recommended hold rating on Lupin with a target price of Rs 1675 in its research report dated May 07, 2024.
High raw material costs dragged Lupin's Q4 net profit to below the Street's estimate, however, the sharp margin improvement provided much cushion to investor sentiment.
Lupin Q4: Revenue came in at Rs 4895.11 crore, up 13 percent from the year-ago quarter of Rs 4,330.3 crore.
Incred Equities estimates Mirabegron to be a $75-80 million opportunity for Zydus Lifesciences, as the company also enjoys a 180-day exclusivity period
Mirabegron Extended-Release tablets had estimated annual sales of $1,019 million in the US
Sharekhan is bullish on Lupin has recommended buy rating on the stock with a target price of Rs 1868 in its research report dated April 15, 2024.